Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/715446/000151316220000009/form10k.htm
Document And Entity Information - USD ($) | 12 Months Ended | ||
|---|---|---|---|
Oct. 31, 2019 | Jan. 08, 2020 | Apr. 30, 2019 | |
| Document Information Line Items | |||
| Entity Registrant Name | Anixa Biosciences Inc | ||
| Document Type | 10-K | ||
| Current Fiscal Year End Date | --10-31 | ||
| Entity Common Stock, Shares Outstanding | 20,821,204 | ||
| Entity Public Float | $ 72,311,537 | ||
| Amendment Flag | false | ||
| Entity Central Index Key | 0000715446 | ||
| Entity Current Reporting Status | Yes | ||
| Entity Voluntary Filers | No | ||
| Entity Filer Category | Non-accelerated Filer | ||
| Entity Well-known Seasoned Issuer | No | ||
| Document Period End Date | Oct. 31, 2019 | ||
| Document Fiscal Year Focus | 2019 | ||
| Document Fiscal Period Focus | FY | ||
| Entity Small Business | true | ||
| Entity Emerging Growth Company | false | ||
| Entity Shell Company | false | ||
| Entity Ex Transition Period | false | ||
| Entity Interactive Data Current | Yes |
View differences made from one year to another to evaluate Anixa Biosciences Inc's financial trajectory
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Anixa Biosciences Inc.
Anixa Biosciences Inc
Email AlertsAnnual Reports
-
10-K Annual Report January 2020
- 10-K Annual Report January 2019
Neutral
78.57% Sentiment
Filter by Sentiment:
Filter by Category:
Filter by Subcategory:
-
Revenue - Product Highlight
Cash provided by financing activities was approximately $5,734,000, resulting from the sale of 1,363,872 shares of common stock in an at-the-market equity offering of approximately $5,527,000, the proceeds from exercise of stock options of approximately $122,000, the proceeds from settlement of a shareholder derivative complaint of approximately $45,000 and the proceeds from the sale of common stock pursuant to employee stock purchase plan of approximately $39,000.
-
Other - Other Highlight
The net loss attributable to noncontrolling interest, representing Wistar's 5% ownership interest in Certainty's net loss, decreased by approximately $75,000 to approximately $172,000 in fiscal year 2019, from approximately $247,000 in fiscal year 2018, as Certainty's net loss decreased.
-
Revenue - Product Highlight
Accordingly, the performance obligations from these licenses were satisfied and 100% of the revenue was recognized upon execution of the license agreement.
-
Revenue - Product Highlight
As such, the performance obligation is satisfied and revenue is recognized upon the execution of the agreement.
-
Financial - Expense Highlight
The decrease in research and development expenses was primarily due to a decrease of approximately $1,410,000 in employee stock option compensation expense, a decrease in employee stock award compensation expense of approximately $351,000 and a decrease in license fees of approximately $190,000, offset by an increase in Certainty's outside research and development expense, excluding license expense, primarily related to its collaboration agreement with Moffitt of approximately $344,000, an increase in Anixa Diagnostics' outside research and development expense, excluding license expense, primarily related to its agreement with our development partner, ResearchDx, of approximately $193,000 and an increase in depreciation expense of approximately $30,000.
-
Financial - Expense
Research and development expenses are...Read more
-
Financial - Expense
The decrease in Certainty's net...Read more
-
Financial - Cash Flow
We can give no assurance...Read more
-
Financial - Cash Flow
The impairment in carrying amount...Read more
-
Financial - Cash Flow
The impairment in carrying amount...Read more
-
Other - Other
As a result, our cash,...Read more
-
Financial - Shares
Further, we have an additional...Read more
-
Financial - Expense
General and administrative expenses decreased...Read more
-
Revenue - Product
Additionally, the sale of equity...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-K Annual Report
SEC Filing Financial Summary
Excel Download
Loading SEC Filing Financial Summary...
Material Contracts, Statements, Certifications & more
Anixa Biosciences Inc provided additional information to their SEC Filing as exhibits
SEC Filing Exhibit
PDF Download
Loading SEC Filing Exhibit...
Form Type: 10-K Annual Report
Accession Number: 0001513162-20-000009
Submitted to the SEC: Thu Jan 09 2020 4:16:35 PM EST
Accepted by the SEC: Thu Jan 09 2020
Period: Thursday, October 31, 2019
Industry: Medical Laboratories
External Resources:
Insider Transactions
Stock Quote
Social Media
Bookmark the Permalink: https://last10k.com/sec-filings/anix/0001513162-20-000009.htm
